Olfactory Dysfunction in beta Thalassemia Major Patients Treated With Iron-Chelating Agents


Creative Commons License

Derin S., ERDOĞAN S. , Sahan M., Azik M. F. , Derin H., Topal Y., ...Daha Fazla

ENT-EAR NOSE & THROAT JOURNAL, cilt.98, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 98 Konu: 8
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1177/0145561319840079
  • Dergi Adı: ENT-EAR NOSE & THROAT JOURNAL

Özet

Ocular and ophthalmological adverse effects may be seen in beta-thalassemia major (BTM) patients treated with regular blood transfusions and iron-chelating agents. We hypothesized that olfactory dysfunction may be present in this population. In this study, we aimed to investigate olfactory dysfunction in patients with BTM and determine the etiological factors. A total of 43 patients with BTM were included in the study. Forty-three patients without any nasal complaints, history of facial trauma, or nasal surgery were included as the controls. All participants had nasal endoscopy. The iron-chelating agents used, their duration of use, as well as hemoglobin and ferritin levels of the BTM patients were recorded. Sniffin' Sticks test (SST) was used to assess olfactory functions, and BTM and control groups were compared for the results. The correlations of SST scores with the other study parameters were analyzed. Eight (18.6%) of 43 patients in the BTM group had hyposmia while none of the patients in the control group had hyposmia (P < .001). Older age, low-hemoglobin level, and longer use of deferoxamine were found to be correlated with olfactory dysfunction. Olfactory dysfunction may be seen in BTM patients treated with iron-chelating agents. The results of this study suggest that screening for olfactory function may be needed in routine follow-up of BTM patients.